[go: up one dir, main page]

DE69940354D1 - Adenovirus-formulierungen zur gentherapie - Google Patents

Adenovirus-formulierungen zur gentherapie

Info

Publication number
DE69940354D1
DE69940354D1 DE69940354T DE69940354T DE69940354D1 DE 69940354 D1 DE69940354 D1 DE 69940354D1 DE 69940354 T DE69940354 T DE 69940354T DE 69940354 T DE69940354 T DE 69940354T DE 69940354 D1 DE69940354 D1 DE 69940354D1
Authority
DE
Germany
Prior art keywords
infectivity
adenovirus
gene therapy
formulations
adenovirus formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940354T
Other languages
English (en)
Inventor
Shuyuan Zhang
Zheng Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Introgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgen Therapeutics Inc filed Critical Introgen Therapeutics Inc
Application granted granted Critical
Publication of DE69940354D1 publication Critical patent/DE69940354D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69940354T 1998-11-16 1999-11-16 Adenovirus-formulierungen zur gentherapie Expired - Lifetime DE69940354D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10860698P 1998-11-16 1998-11-16
US13311699P 1999-05-07 1999-05-07
PCT/US1999/027177 WO2000029024A1 (en) 1998-11-16 1999-11-16 Formulation of adenovirus for gene therapy

Publications (1)

Publication Number Publication Date
DE69940354D1 true DE69940354D1 (de) 2009-03-12

Family

ID=26806075

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940354T Expired - Lifetime DE69940354D1 (de) 1998-11-16 1999-11-16 Adenovirus-formulierungen zur gentherapie

Country Status (8)

Country Link
EP (2) EP1977764A1 (de)
AT (1) ATE421337T1 (de)
AU (1) AU1729600A (de)
CA (1) CA2350890C (de)
DE (1) DE69940354D1 (de)
DK (1) DK1133316T3 (de)
ES (1) ES2323991T3 (de)
WO (1) WO2000029024A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399385B1 (en) 1999-09-29 2002-06-04 The Trustees Of The University Of Pennsylvania Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
GB2408750B (en) * 2003-12-02 2008-12-10 Arthur A Codd Preservation of biological material
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
ES2357772T3 (es) 2004-06-14 2011-04-29 Ishihara Sangyo Kaisha, Ltd. Composición liofilizada de envuelta viral inactivada con actividad de fusión de membrana.
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
CN104984352A (zh) 2005-11-21 2015-10-21 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
CL2007003209A1 (es) 2006-11-07 2008-05-09 Acambis Inc Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
JP6023696B2 (ja) 2010-03-31 2016-11-09 スタビリテック リミテッド ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
EP2552478B1 (de) 2010-03-31 2016-12-21 Stabilitech Ltd. Hilfsstoffe zur stabilisierung von viralen partikeln
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
BR112013005049A2 (pt) * 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
MX350932B (es) 2010-12-02 2017-09-26 Oncolytics Biotech Inc Formulaciones virales liquidas.
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
US20120219590A1 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (pl) 2012-03-12 2016-10-31 Partie rekombinowanych adenowirusów o zmienionych końcach
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CN103316356B (zh) * 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
SG11201405804YA (en) 2012-03-22 2014-10-30 Crucell Holland Bv Vaccine against rsv
CN102755325B (zh) * 2012-07-04 2013-05-29 深圳信立泰药业股份有限公司 一种头孢西丁钠药物组合物、其粉针剂及其制备方法
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
PE20160045A1 (es) 2013-06-17 2016-02-18 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
PL3046536T3 (pl) 2013-09-19 2019-06-28 Janssen Vaccines & Prevention B.V. Ulepszone formulacje adenowirusów
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
US20180028626A1 (en) 2015-02-13 2018-02-01 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
US20180094280A1 (en) * 2015-03-20 2018-04-05 Bluebird Bio, Inc. Vector formulations
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016289492B2 (en) 2015-07-07 2022-08-11 Janssen Vaccines & Prevention B.V. Vaccine against RSV
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
CN105219645B (zh) * 2015-11-06 2018-09-25 南京农业大学 一种微生物保护剂及其应用
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
EP3534922B1 (de) * 2016-11-04 2024-04-17 Takeda Pharmaceutical Company Limited Adeno-assoziierte virusformulierungen
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3624844A1 (de) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
CN108703952B (zh) * 2018-08-16 2021-05-07 张志刚 一种猪瘟口服弱毒冻干疫苗用冻干保护剂及应用
EP3880243A1 (de) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilisierte präfusionierte rsv-f-proteine
US20220143115A1 (en) * 2019-04-19 2022-05-12 Regenxbio Inc. Adeno-Associated Virus Vector Formulations and Methods
BR112022001881A2 (pt) * 2019-08-29 2022-06-21 Astellas Pharma Inc Vírus vaccinia oncolítico geneticamente manipulado e métodos de usos do mesmo
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
MX2023009738A (es) 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN116904617A (zh) * 2022-05-13 2023-10-20 北京中科生仪科技有限公司 一种斑疹伤寒核酸检测引物探针组合物及一体化微流控芯片试剂盒
KR102838310B1 (ko) * 2022-12-22 2025-07-25 주식회사 락토메이슨 유산균 동결보호제
CN117414432B (zh) * 2023-10-24 2025-12-05 北京智飞绿竹生物制药有限公司 一种稳定腺病毒载体冻干制剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0761955B2 (ja) * 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥a型肝炎ワクチン
PT713397E (pt) * 1992-03-24 2003-04-30 United Cancer Res Inst Vacina que contem virus vivos
US5994314A (en) * 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
AU7971194A (en) * 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
CA2181066A1 (en) * 1994-01-12 1995-07-20 Hitoshi Kotani Purification of retroviral vectors
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
IL137510A0 (en) * 1998-02-17 2001-07-24 Schering Corp Compositions comprising viruses and methods for concentrating virus preparations

Also Published As

Publication number Publication date
ES2323991T3 (es) 2009-07-28
ATE421337T1 (de) 2009-02-15
EP1133316B1 (de) 2009-01-21
DK1133316T3 (da) 2009-05-25
CA2350890C (en) 2014-07-08
CA2350890A1 (en) 2000-05-25
EP1977764A1 (de) 2008-10-08
WO2000029024A1 (en) 2000-05-25
WO2000029024A9 (en) 2000-11-02
AU1729600A (en) 2000-06-05
EP1133316A1 (de) 2001-09-19

Similar Documents

Publication Publication Date Title
ATE421337T1 (de) Adenovirus-formulierungen zur gentherapie
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
ATE387492T1 (de) Verfahren und zusammensetzung zur konservierung von adenoviren
ATE253063T1 (de) 5-ht1f-agonisten
DK0812198T3 (da) Stabilisering af prostaglandinpræparater
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
DE60237696D1 (de) Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
BR9815419A (pt) genes desaturase e uso dos mesmos
DE69717815D1 (de) Verbesserungen von kreatin-zusammensetzungen
PT1233784E (pt) Composições e métodos para a estabilização de moléculas biológicas após a liofilização
EE9800248A (et) Külmkuivatatud, vesiikuleid sisaldav ultraheli kontrastaine, selle valmistamismeetod ning ladustamise ja transpordi meetod, ultraheli kontrastaine keskkond ja selle valmistamismeetod ning külmkuivatuse stabilisaatorite kasutamine
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
DE60126760D1 (de) Vektorkonstrukte
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
BR0007201A (pt) Composições incluindo agentes de preservação demalto-oligossacarìdeos reduzidos, e métodospara preservar um material
ATE264340T1 (de) Stabilisierung von gefriergetrocknetem kuchen
ATE226449T1 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
DE60100666D1 (de) Tierärztliche zusammensetzungen zur behandlung von parasiterkrankungen
GB2349335A (en) Compositions
WO1999061039A3 (en) Novel composition for modulating ischemic cell death
DE69518319D1 (de) Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
AR034494A1 (es) Composiciones para el tratamiento del cabello.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CRUCELL HOLLAND B.V., LEIDEN, NL